NLM Digital Collections

Search

Start Over Copyright Public domain ✖Remove constraint Copyright: Public domain Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later

15. WIC reauthorization: opportunities for improving the nutritional status of women, infants, and children

Author(s):
Fox, Harriette.
Publication:
Washington, D.C. : George Washington University, National Health Policy Forum, [2003]
Subject(s):
Child Welfare -- legislation & jurisprudence
Eligibility Determination -- economics
Infant Welfare -- legislation & jurisprudence
Maternal Welfare -- legislation & jurisprudence
Nutrition Policy -- legislation & jurisprudence
Public Assistance -- economics
Child
Child Nutritional Physiological Phenomena
Maternal Nutritional Physiological Phenomena
Nutritional Status
United States
Special Supplemental Nutrition Program for Women, Infants, and Children (U.S.)

31. Rebalancing long-term care: the role of the Medicaid HCBS waiver program

Publication:
Washington, D.C. : National Health Policy Forum, [2006]
Subject(s):
Community Health Services -- economics
Deinstitutionalization -- economics
Home Care Services -- economics
Long-Term Care -- economics
Medicaid -- economics
Community Health Services -- legislation & jurisprudence
Community Health Services -- trends
Costs and Cost Analysis
Deinstitutionalization -- legislation & jurisprudence
Deinstitutionalization -- trends
Eligibility Determination
Forecasting
Home Care Services -- legislation & jurisprudence
Home Care Services -- trends
Long-Term Care -- legislation & jurisprudence
Long-Term Care -- trends
Medicaid -- legislation & jurisprudence
Medicaid -- trends
State Government
Humans
United States

33. Medicare and mental health: the fundamentals

Publication:
Washington, D.C. : George Washington University, [2006]
Subject(s):
Insurance Coverage
Medicare -- economics
Mental Disorders -- economics
Mental Health -- statistics & numerical data
Community Mental Health Services -- economics
Disabled Persons
Disease Management
Drug Costs
Health Expenditures
Hospitalization -- economics
Insurance, Pharmaceutical Services
Medicaid -- economics
Medicare -- statistics & numerical data
Mental Disorders -- epidemiology
Mental Disorders -- therapy
Mental Health Services -- economics
Prevalence
Psychotropic Drugs -- economics
Humans
United States
Medicare Payment Advisory Commission (U.S.)

34. Value-based coverage policy in the United States and the United Kingdom: different paths to a common goal

Publication:
Washington, D.C. : George Washington University, [2006]
Subject(s):
Cost-Benefit Analysis
Evidence-Based Medicine
Insurance Coverage -- economics
Technology Assessment, Biomedical
Formularies as Topic
Medicaid -- economics
Medicare -- economics
Private Sector
State Government
Humans
United Kingdom
United States
United States. Agency for Healthcare Research and Quality.
Blue Cross Association.
Blue Shield Association.
Centers for Medicare & Medicaid Services (U.S.)
National Institute for Health and Clinical Excellence (Great Britain)

35. Health care price transparency and price competition

Publication:
Washington, D.C. : George Washington University, [2007]
Subject(s):
Disclosure
Economic Competition
Health Care Costs
Community Participation -- economics
Contract Services -- economics
Cost Sharing -- economics
Costs and Cost Analysis -- standards
Deductibles and Coinsurance -- economics
Government
Health Benefit Plans, Employee -- economics
Medical Savings Accounts -- economics
Medicare
Preferred Provider Organizations -- economics
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)
Medicare Payment Advisory Commission (U.S.)

37. The prescription drug safety net: access to pharmaceuticals for the uninsured

Publication:
Washington, D.C. : George Washington University, [2007]
Subject(s):
Health Services Accessibility
Medical Assistance
Pharmaceutical Services
Uncompensated Care
Adult
Charities
Drug Industry
Drug Prescriptions -- economics
Economics, Pharmaceutical
Government Programs
HIV Infections -- drug therapy
Insurance, Pharmaceutical Services -- statistics & numerical data
Medically Uninsured
Middle Aged
Physician's Role
Practice Patterns, Physicians'
Humans
United States
United States. Health Resources and Services Administration.

41. Shaping Medicaid and SCHIP through waivers: the fundamentals

Publication:
Washington, D.C. : George Washington University, [2008]
Subject(s):
Child Health Services -- economics
Child Health Services -- legislation & jurisprudence
Medicaid -- economics
Medicaid -- legislation & jurisprudence
Budgets
Child
Child Health Services -- trends
Cost Control
Federal Government
Forecasting
Health Policy -- economics
Medicaid -- trends
Organizational Innovation
Organizational Policy
State Government
Humans
United States
State Children's Health Insurance Program (U.S.)

42. The Ryan White HIV/AIDS Program: the basics

Publication:
Washington, D.C. : George Washington University, [2010]
Subject(s):
Acquired Immunodeficiency Syndrome -- economics
HIV Infections -- economics
Medical Assistance -- legislation & jurisprudence
Acquired Immunodeficiency Syndrome -- therapy
Antiretroviral Therapy, Highly Active -- economics
Government Programs
HIV Infections -- therapy
Medical Assistance -- economics
Medically Uninsured
Humans
United States
United States.

46. The Medicare drug benefit coverage gap: the basics

Publication:
Washington, D.C. : George Washington University, [2011]
Subject(s):
Insurance Coverage -- economics
Insurance Coverage -- legislation & jurisprudence
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- legislation & jurisprudence
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Drug Costs -- statistics & numerical data
Drug Prescriptions -- economics
Financing, Personal -- economics
Financing, Personal -- legislation & jurisprudence
Humans
United States

47. National spending for long-term services and supports (LTSS): the basics

Publication:
Washington, D.C. : George Washington University, [2011]
Subject(s):
Health Expenditures -- statistics & numerical data
Long-Term Care -- economics
Long-Term Care -- statistics & numerical data
Caregivers -- economics
Community Health Services -- economics
Financing, Personal
Health Services Needs and Demand
Home Care Services -- economics
Insurance, Long-Term Care -- economics
Medicaid -- economics
Medicare -- economics
Private Sector
Public Sector
Humans
United States

49. Classification of products as drugs and devices & additional product classification issues: final guidance : guidance for industry and FDA staff

Publication:
Silver Spring, MD : Office of Combination Products, Food and Drug Administration, September 2017
Subject(s):
Biological Products -- classification
Classification -- methods
Equipment and Supplies -- classification
Pharmaceutical Preparations -- classification
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

50. Advancement of emerging technology applications for pharmaceutical innovation and modernization

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, September 2017
Subject(s):
Biomedical Technology -- standards
Drug Industry -- standards
Inventions
Quality Assurance, Health Care
Quality Improvement
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

51. Compliance policy for required warning statements on small-packaged cigars

Publication:
Silver Spring, MD : Center for Tobacco Products, Food and Drug Administration, September 2017
Subject(s):
Product Labeling -- standards
Product Packaging -- standards
Tobacco Products -- standards
Guideline Adherence
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

52. Center for Devices and Radiological Health appeals processes: questions and answers about 517A : guidance for industry and Food and Drug Administration staff

Publication:
[Silver Spring, Maryland] : Center for Devices and Radiological Health, September 29, 2017
Subject(s):
Device Approval -- standards
Documentation -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
United States.

53. Developing and responding to deficiencies in accordance with the least burdensome provisions: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, September 29, 2017
Subject(s):
Device Approval -- standards
Communication
Documentation -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

54. Requests for feedback on medical device submissions: the pre-submission program and meetings with Food and Drug Administration staff : guidance for industry and Food and Drug Administration staff

Publication:
[Silver Spring, Maryland] : Center for Devices and Radiological Health, September 29, 2017
Subject(s):
Device Approval -- standards
Clinical Protocols
Research Design
Telecommunications
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

55. Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, October 2, 2017
Subject(s):
Clinical Laboratory Techniques
Device Approval -- standards
Diagnostic Test Approval -- standards
In Vitro Techniques -- standards
Reagent Kits, Diagnostic -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

56. Display devices for diagnostic radiology: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, October 2, 2017
Subject(s):
Data Display -- standards
Image Processing, Computer-Assisted -- standards
Radiology Information Systems -- standards
Device Approval -- standards
Product Labeling -- standards
Software -- standards
Technology, Radiologic -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

57. M4 organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, October 2017
Subject(s):
Documentation -- standards
Drug Approval
Congresses as Topic
European Union
International Cooperation
Pharmaceutical Preparations -- standards
Humans
Canada
Europe
Japan
Switzerland
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

59. Deciding when to submit a 510(k) for a change to an existing device: guidance for Industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, October 25, 2017
Subject(s):
Device Approval -- standards
Equipment Design -- standards
Equipment Safety -- standards
Product Labeling -- standards
Reagent Kits, Diagnostic -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

60. Deciding when to submit a 510(k) for a software change to an existing device: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, October 25, 2017
Subject(s):
Device Approval -- standards
Software -- standards
Computer Security
Equipment Design -- standards
Equipment Safety -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

61. De novo classification process (evaluation of automatic class III designation): guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, October 30, 2017
Subject(s):
Classification
Device Approval -- standards
Equipment and Supplies -- classification
Equipment Safety -- classification
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

62. Product labeling for certain ultrasonic surgical aspirator devices: guidance for Industry and Food and Drug Administration staff

Publication:
[Silver Spring, Maryland] : Center for Devices and Radiological Health, October 30, 2017
Subject(s):
Product Labeling -- standards
Ultrasonic Surgical Procedures -- instrumentation
Ultrasonic Surgical Procedures -- standards
Equipment Safety -- standards
Leiomyoma -- surgery
Suction -- instrumentation
Suction -- standards
Surgical Equipment -- adverse effects
Ultrasonic Surgical Procedures -- adverse effects
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

63. Manufacturers sharing patient-specific information from medical devices with patients upon request: guidance for industry and Food and Drug Administration staff

Publication:
[Silver Spring, Maryland] : Center for Devices and Radiological Health, October 30, 2017
Subject(s):
Access to Information
Equipment and Supplies -- standards
Health Records, Personal
Information Dissemination
Patient-Centered Care
Health Policy
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

64. Formal dispute resolution: sponsor appeals above the division level : guidance for industry and review staff : good review practice

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, November 2017
Subject(s):
Dissent and Disputes
Investigational New Drug Application
Negotiating
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

66. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, November 2017
Subject(s):
Antiviral Agents -- therapeutic use
Clinical Trials as Topic
Drug Evaluation, Preclinical -- standards
Drugs, Investigational -- therapeutic use
Hepatitis C, Chronic -- drug therapy
Antiviral Agents -- pharmacokinetics
Drugs, Investigational -- pharmacokinetics
Research Design -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

67. Recurrent herpes labialis: developing drugs for treatment and prevention

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, November 2017
Subject(s):
Antiviral Agents -- therapeutic use
Clinical Trials as Topic
Drug Evaluation, Preclinical
Drugs, Investigational -- therapeutic use
Herpes Labialis -- drug therapy
Herpes Labialis -- prevention & control
Research Design -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

68. Evaluating drug effects on the ability to operate a motor vehicle

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, November 2017
Subject(s):
Automobile Driving
Driving Under the Influence
Drug Evaluation -- standards
Psychotropic Drugs -- adverse effects
Evaluation Studies as Topic
Reaction Time -- drug effects
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

69. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use : guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, December 2017
Subject(s):
Autografts -- standards
Biological Products -- standards
Biological Products -- therapeutic use
Tissue Transplantation -- standards
Transplantation, Autologous
Transplantation, Homologous
Transplants -- standards
Prostheses and Implants -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

70. Same surgical procedure exception under 21 CFR 1271.15(b): questions and answers regarding the scope of the exception

Publication:
Silver Spring, MD : Center for Biologics Evaluation and Research, November 2017
Subject(s):
Autografts -- standards
Biological Products -- standards
Biological Products -- therapeutic use
Tissue Transplantation
Transplantation, Autologous
Transplantation, Homologous
Transplants -- standards
Prostheses and Implants -- standards
Surgical Procedures, Operative
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

71. Unique device identification: direct marking of devices : guidance for Industry and Food and Drug administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, November 17, 2017
Subject(s):
Equipment and Supplies -- standards
Equipment Reuse -- standards
Product Labeling -- standards
Device Approval -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

72. General principles for evaluating the abuse deterrence of generic solid oral opioid drug products

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, November 2017
Subject(s):
Abuse-Deterrent Formulations -- standards
Analgesics, Opioid -- administration & dosage
Drugs, Generic
Investigational New Drug Application
Administration, Oral
Administration, Inhalation
Clinical Trials as Topic
Drug Evaluation, Preclinical
Injections
Research Design
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

73. Pediatric information for x-ray imaging device premarket notifications: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, November 28, 2017
Subject(s):
Equipment Safety -- standards
Product Labeling -- standards
Radiation Dosage
Radiation Exposure -- adverse effects
Radiation Exposure -- standards
Radiography -- adverse effects
Radiography -- instrumentation
Adolescent
Child
Child, Preschool
Contraindications
Fluoroscopy -- adverse effects
Fluoroscopy -- instrumentation
Infant
Infant, Newborn
Radiation, Ionizing
Tomography Scanners, X-Ray Computed -- standards
Tomography, X-Ray Computed -- adverse effects
Young Adult
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

74. Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry

Publication:
Silver Spring, MD : Center for Biologics Evaluation and Research, December 2017
Subject(s):
Blood Donors
Donor Selection -- standards
Hepacivirus
Hepatitis C -- blood
HIV Infections -- blood
HIV-1
RNA, Viral -- blood
Blood -- virology
Blood Transfusion
Disease Transmission, Infectious -- prevention & control
Nucleic Acid Amplification Techniques
Polymerase Chain Reaction
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

75. FDA categorization of investigational device exemption (IDE) devices to assist the Centers for Medicare and Medicaid Services (CMS) with coverage decisions: guidance for sponsors, clinical investigators, industry, institutional review boards, and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, December 5, 2017
Subject(s):
Device Approval
Equipment and Supplies
Insurance Coverage
Medicare -- economics
Therapies, Investigational
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
Centers for Medicare & Medicaid Services (U.S.)

76. Technical considerations for additive manufactured medical devices: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Biologics Evaluation and Research, December 5, 2017
Subject(s):
Computer-Aided Design -- standards
Device Approval
Manufactured Materials -- standards
Materials Testing -- standards
Printing, Three-Dimensional -- standards
Quality Control
Computer Security -- standards
Diagnostic Imaging
Models, Anatomic
Product Labeling -- standards
Reproducibility of Results
Software -- standards
Sterilization -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

77. Use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in blood and blood components

Publication:
Silver Spring, MD : Center for Biologics Evaluation and Research, December 2017
Subject(s):
Blood Donors
Chagas Disease -- blood
Chagas Disease -- transmission
Disease Transmission, Infectious -- prevention & control
Donor Selection
Serologic Tests
Trypanosoma cruzi
Chagas Disease -- prevention & control
Risk Management
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

78. Software as a medical device (SAMD): clinical evaluation : guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, December 8, 2017
Subject(s):
Equipment and Supplies -- standards
Reproducibility of Results
Software -- standards
International Cooperation
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

80. Systemic antibacterial and antifungal drugs: susceptibility test interpretive criteria labeling for NDAs and ANDAs

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, December 2017
Subject(s):
Antibacterial Agents
Antifungal Agents
Drug Labeling -- standards
Investigational New Drug Application
Microbial Sensitivity Tests
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

81. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, December 2017
Subject(s):
Biological Availability
Drugs, Investigational -- pharmacokinetics
Investigational New Drug Application
Therapeutic Equivalency
Administration, Oral
Biopharmaceutics -- classification
Drugs, Investigational -- administration & dosage
Excipients
Permeability
Prodrugs
Solubility
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

82. Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, December 2017
Subject(s):
Communication
Drug Industry
Investigational New Drug Application
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

83. Unique device identification: policy regarding compliance dates for class I and unclassified devices : immediately in effect guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Biologics Evaluation and Research, January 16, 2018
Subject(s):
Equipment and Supplies -- classification
Product Labeling -- standards
Product Packaging -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

84. Compounded drug products that are essentially copies of a commercially available drug product under Section 503A of the Federal Food, Drug, and Cosmetic Act

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, January 2018
Subject(s):
Drug Compounding -- standards
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
United States.

87. Drinking water: EPA should strengthen ongoing efforts to ensure that consumers are protected from lead contamination : report to congressional requesters

Publication:
Washington, D.C. : United States Government Accountability Office, [2006]
Subject(s):
Drinking Water -- analysis
Lead Poisoning -- prevention & control
Environmental Monitoring -- legislation & jurisprudence
Water Pollution, Chemical -- prevention & control
Child Day Care Centers -- legislation & jurisprudence
Schools -- legislation & jurisprudence
United States

90. Data inadequacies undermine CMS's oversight of the inconsistency resolution process for the federal marketplace

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, March 2017
Subject(s):
Data Collection
Eligibility Determination
Health Insurance Exchanges
Cost Sharing
Federal Government
Government Regulation
Humans
United States
United States. Department of Health and Human Services.
United States.
Centers for Medicare & Medicaid Services (U.S.)

91. CMS validated hospital inpatient quality reporting program data, but should use additional tools to identify gaming

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, April 2017
Subject(s):
Economics, Hospital
Insurance, Health, Reimbursement
Quality Indicators, Health Care
Reimbursement, Incentive
Cross Infection
Inpatients
Mandatory Reporting
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

93. CDC generally met its inspection goals for the federal select agent program: however, opportunities exist to strengthen oversight

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, May 2017
Subject(s):
Government Regulation
Security Measures
Toxins, Biological
Federal Government
Laboratories -- standards
Risk Assessment
Risk Management
Humans
United States
United States. Department of Health and Human Services.
Centers for Disease Control and Prevention (U.S.)

95. Round 2 competitive bidding for CPAP/RAD: disrupted access unlikely for devices, inconclusive for supplies

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2017
Subject(s):
Competitive Bidding
Continuous Positive Airway Pressure -- economics
Continuous Positive Airway Pressure -- instrumentation
Durable Medical Equipment -- economics
Health Services Accessibility -- economics
Insurance Coverage -- economics
Insurance, Health, Reimbursement
Medicare -- economics
Respiration, Artificial -- economics
Respiration, Artificial -- instrumentation
Humans
United States
United States. Department of Health and Human Services.

97. OHRP generally conducted its compliance activities independently, but changes would strengthen its independence

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, July 2017
Subject(s):
Human Experimentation -- standards
Patient Rights
Research Subjects
Ethics Committees, Research
Guideline Adherence
Human Experimentation -- ethics
Humans
United States
United States. Department of Health and Human Services.
United States. Department of Health and Human Services. Office for Human Research Protections.

98. HHS's Office of Refugee Resettlement improved coordination and outreach to promote the safety and well-being of unaccompanied alien children

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, July 2017
Subject(s):
Child Welfare
Emigrants and Immigrants
Emigration and Immigration
Refugees
Child
Child Abuse -- prevention & control
Human Trafficking -- prevention & control
Safety
Humans
United States
United States. Department of Health and Human Services.
United States. Department of Homeland Security.

99. Medicare program shared savings accountable care organizations have shown potential for reducing spending and improving quality

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017
Subject(s):
Accountable Care Organizations
Cost Savings
Cost Sharing
Medicare
Quality of Health Care
Cost Control
Facilities and Services Utilization -- statistics & numerical data
Fee-for-Service Plans
Health Expenditures
Quality Indicators, Health Care
Humans
United States
United States. Department of Health and Human Services.

Refine by:

more »

more »

more »

more »

more »

Current results range from 1899 to 2022